Comparative Pharmacology
Head-to-head clinical analysis: NORLESTRIN 28 1 50 versus ORTHO NOVUM 7 14 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLESTRIN 28 1 50 versus ORTHO NOVUM 7 14 21.
NORLESTRIN 28 1/50 vs ORTHO-NOVUM 7/14-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.
One tablet containing 0.5 mg norethindrone/0.035 mg ethinyl estradiol (white tablets) on days 1-14, then one tablet containing 1 mg norethindrone/0.035 mg ethinyl estradiol (peach tablets) on days 15-21, then no tablets for 7 days; repeated cycles.
None Documented
None Documented
Norethindrone: 8 hours; ethinyl estradiol: 12-15 hours; steady state achieved within 5-10 days.
Norethindrone: 10-12 hours (terminal), ethinyl estradiol: 13-27 hours (terminal); clinical context: steady state achieved within 5-7 days
Norethindrone: 40% renal, 60% fecal; ethinyl estradiol: 40% renal, 60% fecal.
Renal: ~40% as glucuronide and sulfate conjugates; Fecal: ~20%; Biliary: minor
Category C
Category C
Oral Contraceptive
Oral Contraceptive